Serum interleukin-6 in systemic sclerosis and its correlation with disease parameters and cardiopulmonary involvement

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 33, Issue 4, 2016, Pages 321-330

  Abdel Magied, Rasha A ^a   Kamel, Shereen R ^a   Said, Azza Farag ^b   Ali, Hazem M ^b   Gawad, Ehab A Abdel ^c   Moussa, Mahmoud M ^c  

^a Minia University   (Egypt)

^b Department of Cardiology ^*  (Egypt)

^c MINIA UNIVERSITY   (Egypt)

Author keywords

Cardiopulmonary Involvement; Interleukin 6; Systemic Sclerosis

Indexed keywords

INTERLEUKIN 6; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COUGHING; DISEASE ACTIVITY; DISEASE DURATION; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FEMALE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SIX MINUTE WALK TEST; SYSTEMIC SCLEROSIS; THORAX PAIN; ADOLESCENT; BLOOD; BREATHING; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CASE CONTROL STUDY; COMPLICATION; DIAGNOSTIC IMAGING; DISABILITY; DOPPLER ECHOCARDIOGRAPHY; EXERCISE TEST; EXERCISE TOLERANCE; HEMODYNAMICS; LUNG; LUNG DISEASES; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; QUESTIONNAIRE; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; UPREGULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CASE-CONTROL STUDIES; DISABILITY EVALUATION; ECHOCARDIOGRAPHY, DOPPLER; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEMODYNAMICS; HUMANS; INTERLEUKIN-6; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RESPIRATION; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; UP-REGULATION; YOUNG ADULT;

EID: 85028502407     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wigley FM. Systemic sclerosis: Clinical features. 2nd ed. London: Mosby; 1998: 1-9.
2. Le Pavec J, Launay D, Mathai SC, Hassoun PM, Humbert M. Scleroderma lung disease.Clin Rev Allergy Immunol 2011: 40: 104-116.
3. Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford); 2009; 3: iii40-iii44.
4. Allanove Y, Meune C, Kahan A. Systemic sclerosis and cardiac dys-function: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008; 20: 697-702.
5. Barnes TC, Anderson ME, Moots RJ. The many faces of interleukin-6: The role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 2011; 721608.
6. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: Association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006; 33: 275-84.
7. Muangchant C, Pope JE. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: A systemic literature review. Clin Exp Rheumatol 2013; 31:122-34.
8. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
9. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, DAngelo S, et al. European multicenter study to define disease activity criteria for systemic sclerosis. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
10. Ostojic P, Damjanov N. Indices of the Scleroderma Assessment Questionnaire (SAQ) can be used to demonstrate change in patientswith systemic sclerosis over time. Joint Bone Spine 2008; 75: 286-90.
11. Cole JC, Khanna D, Clements PJ, Seibold JR, Tashkin DP, Paulus HE, et al.Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. Qual Life Res 2006; 15: 1383-94.
12. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JS. Lung volumes and forced ventilatory flows; workgroup on standardization of respiratory function tests. European Community for coal and steel. Official Position of the European Respiratory Society. EurRespir J 1993; 6:41-52.
13. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretation strategies for lung function tests. EurRespir J 2005; 26:948-68.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
15. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross BH, Spizarny DL, et al. Thin section CT obtained at 10 mm increments versus limited three level thin section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983.
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. American Society of Echocardiographys Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of CardiologyRecommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
17. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
18. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22:107-33.
19. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004; 138:540-546.
20. De Santis M, Bosello S, La Torre G, Capuano A, Tolusso B, Pagliari G, et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res 2005; 6: 96.
21. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: Associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
22. Hasegawa M, Sato S, Ihn H, Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology (Oxford) 1999; 38: 612-617.
23. Bosello S, De Santis M, Lama G, Spanò C, Angelucci C, Tolusso B, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six month follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
24. Jurisic Z, Martinovic-Kaliterna D, Marasovic-Krstulovic D, Perkovic D, Tandara L, Salamunic I, et al. Relationship between interleukin-6 and cardiac involvement in systemic sclerosis. Rheumatology (Oxford) 2013; 52: 1298-1302.
25. Bjerke RD, Tashkin DP, Clements PJ, Chopra SK, Gong H Jr, Bein M. Small airways in progressive systemic sclerosis (PSS). Am J Med 1979; 66: 201-209.
26. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosingalveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
27. Yousif M, Habib R, Esaely H, Yasin R, Sonbol A. Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement. Egyptian Journal of Chest Diseases and Tuberculosis 2015; 64: 237-241.
28. Goldin JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Clements PJ, et al. Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-367.
29. de Azevedo AB, Sampaio-Barros PD, Torres RM, Moreira C. Prevalence of pulmonary hypertension in systemic sclerosis. Clin Exp Rheumatol 2005; 23:447-454.
30. Villalba WO, Sampaio-Barros PD, Pereira MC, Cerqueira EM, Leme CA Jr, Marques-Neto JF, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 217-222.
31. Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nuclear antibody. J Rheumatol 2007; 34: 2230-2235.
32. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34: 1005-1011.
33. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, BoonstraA, Bronzwaer JG, et al. Right ventricular contractility in systemic sclerosis-Associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31: 1160-1166.
34. Ostojic P, Damjanov N. The Scleroderma Assessment Questionnaire (SAQ): A new self-Assessment questionnaire for evaluation of disease status in patients with systemic sclerosis. Z Rheumatol 2006; 65: 168-175.